Literature DB >> 32380057

Is extracorporeal membrane oxygenation withdrawal a safe option after double-lung transplantation?

Julien Fessler1, Edouard Sage1, Antoine Roux1, Elodie Feliot2, Etienne Gayat2, Romain Pirracchio3, François Parquin1, Charles Cerf1, Marc Fischler4, Morgan Le Guen1.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is commonly used during double-lung transplantation. ECMO can be Planned or Unplanned, and used only during the procedure or extended postoperatively (Intraoperative or Extended). Our practice is to limit its use and duration as much as possible. We conducted this retrospective single-center study to assess prognoses of patients undergoing Unplanned-Intraoperative ECMO.
METHODS: From among 436 patients who underwent double-lung transplantation from 2012 to 2018, we excluded those who underwent bridge-to-transplantation, multiorgan transplantation, repeated transplantation during the study period, and cardiopulmonary bypass. Unplanned-Intraoperative ECMO group was compared to No-ECMO and Planned-Intraoperative ECMO groups.
RESULTS: Two hundred nine patients did not require ECMO, 77 underwent Unplanned-Intraoperative ECMO, and 14 underwent Planned-Intraoperative ECMO. One and three-year survival were lower in Unplanned-Intraoperative ECMO group than in No-ECMO group (p=0.043 and p=0.032, respectively). The only independent protective factor related to one-year mortality was history of cystic fibrosis (p=0.013). Lung allocation score (p=0.001), grade 3 pulmonary graft dysfunction at end-surgery status (p=0.014), and estimated intraoperative blood loss (p=0.031) were risk factors.
CONCLUSIONS: Patients who underwent Unplanned-Intraoperative ECMO showed poorer prognoses than patients who did not require ECMO. This finding may be explained by differences in initial condition severity, by long-term consequences of the intraoperative complications leading to ECMO pump implantation, or by flaws in our weaning protocol.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32380057     DOI: 10.1016/j.athoracsur.2020.03.077

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  The Impact of New Treatments on Short- and MID-Term Outcomes in Bilateral Lung Transplant: A Propensity Score Study.

Authors:  Annalisa Boscolo; Andrea Dell'Amore; Tommaso Pettenuzzo; Nicolò Sella; Alessandro De Cassai; Elisa Pistollato; Nicola Cacco; Andrea Manzan; Agnese De Carolis; Federico Geraldini; Giulia Lorenzoni; Federica Pezzuto; Giovanni Zambello; Marco Schiavon; Fiorella Calabrese; Dario Gregori; Emanuele Cozzi; Federico Rea; Paolo Navalesi
Journal:  J Clin Med       Date:  2022-10-03       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.